このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

89bio 将来の成長

Future 基準チェック /26

89bio利益と収益がそれぞれ年間12.9%と74.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-110.4% 18.9%なると予測されています。

主要情報

12.9%

収益成長率

18.9%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	74.7%
将来の株主資本利益率	-110.4%
アナリストカバレッジ	Good
最終更新日	10 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqGM:ETNB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	38	-292	-289	-278	7
12/31/2025	3	-287	-261	-285	7
12/31/2024	1	-239	-203	-222	7
3/31/2024	N/A	-165	-139	-139	N/A
12/31/2023	N/A	-142	-129	-129	N/A
9/30/2023	N/A	-127	-122	-122	N/A
6/30/2023	N/A	-119	-106	-106	N/A
3/31/2023	N/A	-105	-87	-87	N/A
12/31/2022	N/A	-102	-81	-81	N/A
9/30/2022	N/A	-104	-82	-82	N/A
6/30/2022	N/A	-105	-81	-81	N/A
3/31/2022	N/A	-101	-86	-86	N/A
12/31/2021	N/A	-90	-77	-77	N/A
9/30/2021	N/A	-76	-63	-63	N/A
6/30/2021	N/A	-63	-62	-62	N/A
3/31/2021	N/A	-54	-54	-53	N/A
12/31/2020	N/A	-49	-46	-46	N/A
9/30/2020	N/A	-56	-44	-43	N/A
6/30/2020	N/A	-60	-37	-37	N/A
3/31/2020	N/A	-64	-29	-29	N/A
12/31/2019	N/A	-57	-26	-25	N/A
9/30/2019	N/A	-44	-19	-19	N/A
6/30/2019	N/A	-30	-15	-15	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ETNB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ETNB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ETNB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ETNBの収益 ( 74.7% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: ETNBの収益 ( 74.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ETNB 3 年以内に赤字になると予測されています。

89bio 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 9.4% to US$33.44

Price target increased by 7.8% to US$37.44

Consensus EPS estimates upgraded to US$2.01 loss

Price target increased by 34% to US$33.75

Price target increased to US$24.63

Consensus forecasts updated

Recent updates

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company

89Bio Completes Target Enrollment in Histology Cohort to Evaluate Bio89-100 for the Treatment of Nash

Price target decreased to US$52.50

89bio: Undervalued Contender In Race For First NASH Drug Approval

COO & Chief Business Officer exercised options and sold US$104k worth of stock

CEO & Director recently bought US$118k worth of stock

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

COO & Chief Business Officer exercised options and sold US$124k worth of stock

89Bio Initiates Phase 2B Enliven Trial of Bio89-100 for the Treatment of Nash

COO & Chief Business Officer notifies of intention to sell stock

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio, Inc. Announces Additional Positive Data from its Phase 1b/2a Study of BIO89-100 to Be Present at the Annual Endo 2021 Conference

COO & Chief Business Officer exercised options and sold US$156k worth of stock

Independent Director exercised options to buy US$2.0m worth of stock.

89bio: NASH Drug Developer With Differentiated Profile

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely